DE19975064I2 - Tumornekrosefaktor, Verfahren zu seiner Herstellung, denselben enthaltende Zusammensetzungen, daf}r kodierende DNS und diese DNS verwendendes Testverfahren. - Google Patents

Tumornekrosefaktor, Verfahren zu seiner Herstellung, denselben enthaltende Zusammensetzungen, daf}r kodierende DNS und diese DNS verwendendes Testverfahren.

Info

Publication number
DE19975064I2
DE19975064I2 DE1999175064 DE19975064C DE19975064I2 DE 19975064 I2 DE19975064 I2 DE 19975064I2 DE 1999175064 DE1999175064 DE 1999175064 DE 19975064 C DE19975064 C DE 19975064C DE 19975064 I2 DE19975064 I2 DE 19975064I2
Authority
DE
Germany
Prior art keywords
necrosis factor
tumor necrosis
dna
preparation
compositions containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE1999175064
Other languages
German (de)
English (en)
Other versions
DE19975064I1 (de
Inventor
Bharat Bhushan Aggarwal
Sang He Lee
David Vannorman Goeddel
Glenn Evan Nedwin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US06/677,257 external-priority patent/US4650674A/en
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of DE19975064I1 publication Critical patent/DE19975064I1/de
Publication of DE19975064I2 publication Critical patent/DE19975064I2/de
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C07K14/5255—Lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE1999175064 1984-07-05 1985-07-03 Tumornekrosefaktor, Verfahren zu seiner Herstellung, denselben enthaltende Zusammensetzungen, daf}r kodierende DNS und diese DNS verwendendes Testverfahren. Active DE19975064I2 (de)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US62805984A 1984-07-05 1984-07-05
US62795984A 1984-07-05 1984-07-05
US62806084A 1984-07-05 1984-07-05
US67745484A 1984-12-03 1984-12-03
US67715684A 1984-12-03 1984-12-03
US06/677,257 US4650674A (en) 1984-07-05 1984-12-03 Synergistic cytotoxic composition

Publications (2)

Publication Number Publication Date
DE19975064I1 DE19975064I1 (de) 2005-09-29
DE19975064I2 true DE19975064I2 (de) 2005-11-03

Family

ID=27560190

Family Applications (2)

Application Number Title Priority Date Filing Date
DE1999175064 Active DE19975064I2 (de) 1984-07-05 1985-07-03 Tumornekrosefaktor, Verfahren zu seiner Herstellung, denselben enthaltende Zusammensetzungen, daf}r kodierende DNS und diese DNS verwendendes Testverfahren.
DE3587939T Expired - Lifetime DE3587939T2 (de) 1984-07-05 1985-07-03 Tumornekrosefaktor, Verfahren zu seiner Herstellung, denselben enthaltende Zusammensetzungen, dafür kodierende DNS und diese DNS verwendendes Testverfahren.

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE3587939T Expired - Lifetime DE3587939T2 (de) 1984-07-05 1985-07-03 Tumornekrosefaktor, Verfahren zu seiner Herstellung, denselben enthaltende Zusammensetzungen, dafür kodierende DNS und diese DNS verwendendes Testverfahren.

Country Status (20)

Country Link
EP (1) EP0168214B1 (forum.php)
JP (4) JP2557341B2 (forum.php)
AT (1) ATE113295T1 (forum.php)
AU (1) AU599571B2 (forum.php)
BG (1) BG60250B1 (forum.php)
CZ (1) CZ283149B6 (forum.php)
DE (2) DE19975064I2 (forum.php)
DK (2) DK169894B1 (forum.php)
FI (2) FI95472C (forum.php)
GR (1) GR851626B (forum.php)
HU (1) HU209153B (forum.php)
IE (1) IE65426B1 (forum.php)
IL (2) IL75717A (forum.php)
LU (1) LU90456I2 (forum.php)
NL (1) NL990033I2 (forum.php)
NO (1) NO852673L (forum.php)
NZ (1) NZ212632A (forum.php)
PL (1) PL155778B1 (forum.php)
SK (1) SK506785A3 (forum.php)
YU (1) YU47968B (forum.php)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1265444A (en) * 1983-06-27 1990-02-06 Lloyd J. Old Effect of human tumor necrosis factor and human interferon on human cancer cells and methods
EP0155549B1 (en) * 1984-03-06 1991-03-20 Dainippon Pharmaceutical Co., Ltd. Dna encoding human tumor necrosis factor and human tumor necrosis factor polypeptide
US5288852A (en) * 1984-03-06 1994-02-22 Dainippon Pharmaceutical Co., Ltd. Human tumor necrosis factor polypeptides
US5672347A (en) * 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
JP2675294B2 (ja) * 1984-10-15 1997-11-12 カイロン コーポレイション ヒト腫瘍壊死因子
US4959314A (en) 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
IL73883A (en) * 1984-12-20 1990-12-23 Yeda Res & Dev Monoclonal antibodies against tnf-alpha,hybridomas producing them and method for the purification of tnf-alpha
JP2557053B2 (ja) * 1984-12-21 1996-11-27 バイオジェン インコーポレイテッド 腫瘍壊死因子の精製、製造および使用法
JPS61155330A (ja) * 1984-12-28 1986-07-15 Denichi Mizuno 蛋白質標品
JPS6248634A (ja) * 1985-07-23 1987-03-03 Mochida Pharmaceut Co Ltd 新規アミノ酸組成物、その製造方法及び該アミノ酸組成物を含有する医療組成物
US4870163A (en) * 1985-08-29 1989-09-26 New York Blood Center, Inc. Preparation of pure human tumor necrosis factor and hybridomas producing monoclonal antibodies to human tumor necrosis factor
US4894439A (en) * 1986-05-22 1990-01-16 Cetus Corporation N-terminal derivatives of tumor necrosis factor purified by microporous PTFE membranes
US4677197A (en) * 1985-10-30 1987-06-30 Cetus Corporation Purification method for tumor necrosis factor
US4828830A (en) * 1986-01-24 1989-05-09 Genentech, Inc. Method and composition for prophylaxis and treatment of viral infections
NZ219027A (en) * 1986-01-24 1989-09-27 Genentech Inc Antiviral composition containing interferon tumour necrosis factor and/or lymphotoxin
EP0247906B1 (en) * 1986-02-04 1994-12-28 Mizuno, Den'Ichi DNA coding for anti-tumour polypeptides, the polypeptides and anti-tumour agents comprising said polypeptides
US4863727A (en) * 1986-04-09 1989-09-05 Cetus Corporation Combination therapy using interleukin-2 and tumor necrosis factor
US5425940A (en) * 1986-04-09 1995-06-20 Cetus Oncology Corporation Combination therapy using interleukin-2 and tumor necrosis factor
PT85076B (pt) * 1986-06-16 1990-07-31 Genentech Inc Metodo para o tratamento de doencas infecciosas pela administracao de factor de necrose tumoral-alfa
JPH0817712B2 (ja) * 1986-06-20 1996-02-28 大日本製薬株式会社 新規ヒトｔｎｆポリペプチド変異体
EP0251037B1 (en) * 1986-06-20 1994-06-15 Dainippon Pharmaceutical Co., Ltd. Novel human TNF polypeptide mutants and DNAs encoding said mutants
US4857314A (en) * 1986-07-18 1989-08-15 Health Research , Inc. C-reactive proteins in treatment of animal and human cancers
CA1340698C (en) * 1986-07-25 1999-08-10 Kabushiki Kaisha Hayashibara Seibutsu Kaguku Kenkyujo Preparation and uses of interferon-gamma
KR880001300A (ko) * 1986-07-31 1988-04-22 맥스 디. 헨슬리 리트로바이러스 감염의 예방 및 치료를 위한 방법 및 조성물
US5002876A (en) * 1986-09-22 1991-03-26 Phillips Petroleum Company Yeast production of human tumor necrosis factor
US4777242A (en) * 1986-10-10 1988-10-11 Phillips Petroleum Company Purification of recombinant tumor necrosis factor
WO1988006625A2 (en) * 1987-02-26 1988-09-07 Cetus Corporation Arginine-depleted human tumor necrosis factor
US4894225A (en) * 1987-03-02 1990-01-16 Cetus Corporation Combination therapy using antitumor immunotoxins with tumor necrosis factor
JPS6463395A (en) * 1987-05-04 1989-03-09 Oncogen Oncostatin m and novel composition having antitumor activity
DE3837012A1 (de) * 1988-01-15 1989-07-27 Knoll Ag Verwendung von tnf und lt zur herstellung von arzneimitteln
GB2217325B (en) * 1988-04-08 1991-11-20 British Bio Technology Synthetic gene for tumour necrosis factor alpha.
DE3843534A1 (de) * 1988-12-23 1990-07-12 Basf Ag Neue tnf-polypeptide
US5998378A (en) * 1989-08-16 1999-12-07 Chiron Corporation Compositions for the inhibition of TNF hormone formation and uses thereof
DK0491878T3 (da) 1989-08-16 1997-06-23 Chiron Corp Præparater til inhibering af proteinhormondannelse og anvendelser deraf
US5843693A (en) * 1989-08-16 1998-12-01 Chiron Corporation Assay method for screening for inhibitors of proTNF conversion
US6586222B1 (en) 1989-08-16 2003-07-01 Chiron Corporation Recombinant PR-3 and compositions thereof
US5370870A (en) * 1989-10-06 1994-12-06 Genentech, Inc. Method for protection against reactive oxygen species
US5200176A (en) * 1989-10-06 1993-04-06 Genentech, Inc. Method for protection of ischemic tissues using tumor nerosis factor
DE69124795T2 (de) * 1990-03-12 1997-06-26 Peptide Technology Ltd., Dee Why, Neusuedwales Neutrophile stimulierende peptide
IL97779A (en) * 1990-04-10 2000-01-31 Genentech Inc Compositions for cytoprotection against radiation and chemotherapy injury or risk thereof
CA2055168A1 (en) * 1990-11-21 1992-05-22 Walter Fiers Tnf-muteins
CA2155103A1 (en) * 1993-02-03 1994-08-18 Rudolph Lucas Tnf-alpha muteins and a process for preparing them
KR970005042B1 (ko) * 1993-02-09 1997-04-11 한일합성섬유공업 주식회사 종양괴사인자-알파 뮤테인
CA2119089A1 (en) * 1993-03-29 1994-09-30 David Banner Tumor necrosis factor muteins
CA2185162A1 (en) 1994-03-07 1995-09-14 Robert F. Halenback (Deceased) Compositions for the inhibition of tnf formation and uses thereof
US5747023A (en) * 1994-07-01 1998-05-05 Genentech, Inc. Cancer therapy using lymphotoxin
IL120979A0 (en) * 1997-06-02 1997-11-20 Interpharm Lab Ltd Glycosylated TNF
PL2953634T3 (pl) 2013-02-07 2021-11-22 The General Hospital Corporation Sposoby namnażania lub zubożania limfocytów t-regulatorowych

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH65623A (de) * 1913-08-02 1914-07-01 Siemens Ag Zeitrelais mit Wechselstrommotor und dessen Drehmoment entgegenwirkender Feder
NO163060C (no) * 1981-03-13 1990-03-28 Damon Biotech Inc Fremgangsmaate for fremstilling av substanser som dannes av levende celler som produserer interferoner eller antistoffer.
JPS5821621A (ja) * 1981-07-31 1983-02-08 Hayashibara Biochem Lab Inc ヒトツモア・ネクロシス・ファクタ−を含有する悪性腫瘍治療剤
CA1265444A (en) * 1983-06-27 1990-02-06 Lloyd J. Old Effect of human tumor necrosis factor and human interferon on human cancer cells and methods
JPS60226816A (ja) * 1984-11-16 1985-11-12 Asahi Chem Ind Co Ltd 抗腫瘍活性をもつヒト由来蛋白質
JPH0695939B2 (ja) * 1983-12-02 1994-11-30 大日本製薬株式会社 ウサギ癌壊死因子をコ−ドするクロ−ン化ｄνａ
EP0148311B1 (en) * 1983-12-26 1988-07-20 Asahi Kasei Kogyo Kabushiki Kaisha A novel physiologically active polypeptide
JPS60137292A (ja) * 1983-12-26 1985-07-20 Asahi Chem Ind Co Ltd 新規生理活性ポリペプチドの遺伝情報を有するポリデオキシリボ核酸、該ポリデオキシリボ核酸を含む複製可能な組換ｄνａ、該複製可能な組換ｄνａで形質転換された微生物または細胞、新規生理活性ポリペプチド及びその製造方法
JPS60221092A (ja) * 1984-04-18 1985-11-05 Asahi Chem Ind Co Ltd 新規生理活性ポリペプチドのｄｎａ
JPS60166696A (ja) * 1984-02-08 1985-08-29 Asahi Chem Ind Co Ltd 新規生理活性ポリペプチドのｄνａ
JPS60185799A (ja) * 1984-03-06 1985-09-21 Dainippon Pharmaceut Co Ltd ヒト癌壊死因子
JPS60232097A (ja) * 1984-04-23 1985-11-18 Dainippon Pharmaceut Co Ltd ヒト癌壊死因子ポリペプチドの製造法
EP0155549B1 (en) * 1984-03-06 1991-03-20 Dainippon Pharmaceutical Co., Ltd. Dna encoding human tumor necrosis factor and human tumor necrosis factor polypeptide
US4879226A (en) * 1984-04-06 1989-11-07 Asahi Kasei Kogyo Kabushiki Kaisha Novel human physiologically active polypeptide
DE3421731A1 (de) * 1984-06-12 1985-12-12 Boehringer Ingelheim International GmbH, 6507 Ingelheim Humaner-tumor-nekrose-faktor
JP2675294B2 (ja) * 1984-10-15 1997-11-12 カイロン コーポレイション ヒト腫瘍壊死因子
JP2515975B2 (ja) * 1985-02-26 1996-07-10 大日本製薬株式会社 抗腫瘍作用を有するポリペプチド

Also Published As

Publication number Publication date
JPS6140221A (ja) 1986-02-26
EP0168214B1 (en) 1994-10-26
AU599571B2 (en) 1990-07-26
GR851626B (forum.php) 1985-11-26
JPH0928387A (ja) 1997-02-04
FI95472B (fi) 1995-10-31
NL990033I1 (nl) 1999-12-01
YU47968B (sh) 1996-08-13
IL105271A (en) 1995-07-31
LU90456I2 (fr) 1999-12-06
FI98217B (fi) 1997-01-31
HU209153B (en) 1994-03-28
PL155778B1 (pl) 1992-01-31
ATE113295T1 (de) 1994-11-15
SK279897B6 (sk) 1999-05-07
IL75717A (en) 1994-11-28
JPH083061A (ja) 1996-01-09
IL75717A0 (en) 1985-11-29
DK305885D0 (da) 1985-07-04
FI852626L (fi) 1986-01-06
FI943750L (fi) 1994-08-15
JPH07291997A (ja) 1995-11-07
JP2614989B2 (ja) 1997-05-28
BG60250B2 (bg) 1994-03-24
DK171418B1 (da) 1996-10-21
PL254399A1 (en) 1986-06-17
FI98217C (fi) 1997-05-12
NZ212632A (en) 1991-05-28
SK506785A3 (en) 1999-05-07
DE3587939D1 (de) 1994-12-01
DK305885A (da) 1986-03-14
DE19975064I1 (de) 2005-09-29
BG60250B1 (bg) 1994-03-24
IE851691L (en) 1986-01-05
EP0168214A3 (en) 1987-12-16
NL990033I2 (nl) 2000-11-01
YU113285A (en) 1991-04-30
AU4465285A (en) 1986-01-09
CZ283149B6 (cs) 1998-01-14
DE3587939T2 (de) 1995-04-27
DK169894B1 (da) 1995-03-27
DK75694A (da) 1994-06-24
EP0168214A2 (en) 1986-01-15
NO852673L (no) 1986-01-06
JP2557341B2 (ja) 1996-11-27
CZ506785A3 (en) 1997-07-16
HUT38125A (en) 1986-04-28
FI95472C (fi) 1996-02-12
FI852626A0 (fi) 1985-07-03
IE65426B1 (en) 1995-11-01
FI943750A0 (fi) 1994-08-15

Similar Documents

Publication Publication Date Title
DE19975064I2 (de) Tumornekrosefaktor, Verfahren zu seiner Herstellung, denselben enthaltende Zusammensetzungen, daf}r kodierende DNS und diese DNS verwendendes Testverfahren.
MY101852A (en) Tumor necrosis factor, methods for its preparation, containing it, dna encoding it and assay method using such dna.
DE3878627D1 (de) Zusammensetzung zur oberflaechenbehandlung von kautschuk.
HUT43106A (en) Dns sequences koding proteins of flesh-i type inhibitor activity and process for producing these proteins
SE8901342L (sv) Biologiska material, foerfaranden foer framstaellning av biologiska material samt foer anvaendning av saadana material i terapi
EP0676413A3 (en) Interferon alpha / beta binding protein, its production and application.
ES8800984A1 (es) Un metodo para obtener adn que codifica factor de necrosis de tumores mutante